Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • Anal Cancer
  • Cervix Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Penile Cancer
  • Squamous Cell Lung Cancer
  • Vulvar Cancer
Type
Interventional
Phase
Phase 2
Design
Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: 6 independent cohorts (head and neck, cervix, lung, anus, vulva, and penis) evaluating the association of pembrolizumab and vorinostatMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

Open-label, non-randomized, multi-center, basket phase II trial, evaluating the efficacy of pembrolizumab in combination with vorinostat in adult patients with recurrent and/or metastatic squamous cell carcinoma of different locations. Antitumor activity of the combination will be evaluated using th...

Open-label, non-randomized, multi-center, basket phase II trial, evaluating the efficacy of pembrolizumab in combination with vorinostat in adult patients with recurrent and/or metastatic squamous cell carcinoma of different locations. Antitumor activity of the combination will be evaluated using the objective response rate (ORR) during treatment (investigator assessment).

Tracking Information

NCT #
NCT04357873
Collaborators
  • Merck Sharp & Dohme Corp.
  • Fondation ARC
  • ERA-NET
Investigators
Principal Investigator: Christophe Le Tourneau, MD Institut Curie